{
  "url": "https://openlegislation.uk/branded-health-service-medicines-costs-regulations-2018/regulation-3",
  "json_url": "https://openlegislation.uk/branded-health-service-medicines-costs-regulations-2018/regulation-3.json",
  "legislation": "uksi/2018/345",
  "legislation_title": "The Branded Health Service Medicines (Costs) Regulations 2018",
  "legislation_url": "https://openlegislation.uk/branded-health-service-medicines-costs-regulations-2018",
  "path": "regulation/3",
  "kind": "regulation",
  "number": "3",
  "heading": "Payment scheme",
  "text": "(1) Subject to paragraphs (1AA), (1AB), (4) and (5A), the manufacturer or supplier that is responsible for the first relevant supply of an item of presentation must pay for the applicable period specified in the first column of the table below the payment percentage specified in the—\n(a) second column for each newer presentation; or\n(b) third column for each older presentation,\nof that table of the net sales income received in respect of that supply to the Secretary of State in accordance with Schedule 1.\nTable\nApplicable Period\nNewer presentation payment percentage\nOlder presentation payment percentage\n1st July 2026 to the end of 2026\n16.5%\n11%\n1st January 2027 to the end of 2027 and any subsequent calendar year\n16.5%\n10.9%\n(1A) Where, in respect of an applicable period, as a consequence of an amendment to these Regulations, there is an amendment (in any manner) of a payment percentage specified in the second column of the table, the applicable payment percentage for payments payable under paragraph (1) in respect of supplies of an item of presentation under any contract entered into on or after 1st January 2019, including—\n(a) a contract with a contracting authority based on a framework agreement where that framework agreement was entered into following a tender which closed on or after 1stJanuary 2019; or\n(b) a public contract entered into following a tender which closed on or after 1st January 2019,\nis, for that applicable period, the amended percentage.\n(1AA) Subject to paragraph (4A), in addition to any sum that may be required to be paid under paragraph (1)(b), the manufacturer or supplier that is responsible for the first relevant supply of an item of presentation that is an older presentation must pay the payment percentage calculated in accordance with regulation 3A of the net sales income received in respect of that supply to the Secretary of State in accordance with Schedule 1.\n(1AB) Where paragraph (1AC) applies, the newer presentation payment percentage referred to in paragraph (1) for the period beginning on 1st July 2026 and ending at the end of 2026 is 8.7% and not 16.5%.\n(1AC) This paragraph applies in the case of the payments payable under paragraph (1) by a manufacturer or supplier in respect of supplies during the period beginning on 1st July 2026 and ending at the end of 2026, if, in respect of any supply of an item of presentation that was a newer presentation of that manufacturer or supplier—\n(a) a payment was payable under paragraph (1) in respect of a supply during the period beginning on 1st January 2026 and ending at the end of 30 June 2026; and\n(b) the applicable payment percentage was 24.3%.\n(1B) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n(1C) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n(2) Subject to paragraph (3), for these purposes the first relevant supply is the first occasion on which that item of presentation is supplied by any manufacturer or supplier having a place of business in the United Kingdom (MS1) to another person having a place of business in the United Kingdom (MS2) that is not in the same group as MS1.\n(3) If MS2 is—\n(a) the marketing authorisation holder (MAH) in respect of that item of presentation; or\n(b) a manufacturer or supplier in the same group as MAH,\nthe first relevant supply is the next supply of that item of presentation to a person having a place of business in the United Kingdom that is not in the same group as MS2.\n(4) Subject to paragraph (5), paragraphs (1) and (1AA) do not apply to the net sales income received in respect of the supply of—\n(a) any item of presentation which was in respect of that supply, supplied under—\n(i) a contract with a contracting authority based on a framework agreement where that framework agreement was entered into on or before the date of the coming into force of these Regulations or was entered into following a tender which closed on or before the date of the coming into force of these Regulations,\n(ii) a public contract entered into on or before the date of the coming into force of these Regulations or was entered into following a tender which closed on or before the date of the coming into force of these Regulations;\n(b) any item of low cost presentation;\n(c) any item of parallel distributed presentation;\n(d) any item of voluntary scheme presentation;\n(e) any item of new active substance presentation during the period beginning on the date on which the marketing authorisation is granted for the first therapeutic indication of the presentation and ending on the last day of the 36th month after that date;\n(f) any item of presentation which is a line extension of a new active substance presentation to which sub-paragraph (e) applies which is supplied during the period referred to in sub-paragraph (e) for the new active substance presentation;\n(g) any item of exceptional centrally procured presentation;\n(h) any item of centrally procured vaccine presentation.\n(4A) Paragraph (1AA) does not apply to the net sales income received by a manufacturer or supplier in respect of the supply of—\n(a) any item of presentation that is a plasma derived medicinal product; or\n(b) any item of presentation that is an older presentation where the cumulative net sales income from all older presentations with a common relevant virtual therapeutic moiety that the manufacturer or supplier supplies for health service use does not exceed £1,500,000 during a relevant calendar year.\n(5) Paragraph (4)(a) does not apply to any item of presentation added to a framework agreement or public contract after the coming into force of these Regulations.\n(5A) Where paragraph (5B) applies, the payment percentage referred to in paragraph (1) for the applicable period is 7.80% and not the percentage specified in the corresponding entry for that applicable period in the second column of the table.\n(5B) Subject to paragraph (5C), this paragraph applies in respect of payments payable under paragraph (1) in respect of supplies of an item of presentation under—\n(a) a contract with a contracting authority based on a framework agreement where that framework agreement was entered into on or after 1st April 2018 but before 1st January 2019, or was entered into following a tender which closed on or after 1st April 2018 but before 1st January 2019;\n(b) a public contract entered into on or after 1st April 2018 but before 1st January 2019 or was entered into following a tender which closed on or after 1st April 2018 but on or before 1st January 2019.\n(5C) Paragraph (5B) does not apply to payments payable in respect of supplies of any item of presentation added to a framework agreement or public contract that falls within paragraph (5B)(a) or (b) where that item is added on or after 1st January 2019.\n(5D) For the purposes of paragraph (4)(e)—\n(a) “new active substance presentation” means a presentation containing a new active substance with a marketing authorisation incorporating the first therapeutic indication for that active substance, but not other presentations marketed under a different brand name which nevertheless contain that new active substance (whether alone or in combination with other active substances); and\n(b) a presentation is only to be considered to contain a new active substance where confirmation that the presentation contains a new active substance is provided by—\n(i) a European Public Assessment Report published by the European Medicines Agency in relation to the presentation in accordance with Article 13.3 of the Regulation (EC) 726/2004 of the European Parliament and of the Council of 31st March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, or\n(ii) a assessment report published by the licensing authority in accordance with regulation 64(6) of the 2012 Regulations.\n(5E) For the purposes of paragraph (4)(f), “line extension” means a new presentation with the same active substance as another presentation which is marketed under the same brand name and by the same manufacturer or supplier but is distinguishable by reference to its strength, an excipient, its pack size, its method of administration or its formulation.\n(5F) For the purposes of paragraph (4)(g), “exceptional centrally procured presentation” means a presentation which—\n(a) is part of stock procured by the Secretary of State;\n(b) is procured for the purpose of emergency preparedness or stockpiling for national security or pandemic preparedness; and\n(c) either—\n(i) UKHSA manages the stockpiling and distribution of the relevant presentation, or\n(ii) the Secretary of State gives a direction to the manufacturer or supplier to the effect that paragraph (i) need not be satisfied in relation to the relevant presentation.\n(5G) For the purposes of paragraph (4)(h), “centrally procured vaccine presentation” means a presentation which—\n(a) is part of stock procured by the Secretary of State;\n(b) is a vaccine procured in accordance with a recommendation made or advice given by the Joint Committee on Vaccination and Immunisation—\n(i) for a national vaccination programme, or\n(ii) for a branded medicine to be included in a national vaccination programme; and\n(c) either—\n(i) UKHSA manages the distribution of the vaccine as part of a national vaccination programme, or\n(ii) the Secretary of State gives a direction to the manufacturer or supplier to the effect that paragraph (i) need not be satisfied in relation to the relevant presentation.\n(5H) In this regulation—\n“active substance” has the meaning given in regulation 8(1) of the 2012 Regulations;\n“licensing authority” is to be construed in accordance with regulation 6 of the 2012 Regulations;\n“plasma derived medicinal product” means a presentation that includes an active ingredient from any of the following virtual therapeutic moieties—\n(a)albumin human;\n(b)anti-D immunoglobulin;\n(c)C1- esterase inhibitor;\n(d)factor VIII plus von Willebrand factor;\n(e)factor X;\n(f)factor XIII;\n(g)fibrinogen;\n(h)high purity factor IX;\n(i)human alpha1 -proteinase inhibitor;\n(j)human prothrombin complex concentrate;\n(k)normal immunoglobulin human;\n(l)protein C human; or\n(m)von Willebrand factor;\n“UKHSA” means the executive agency of the Department of Health and Social Care known as the United Kingdom Health Security Agency; and\n“vaccine” has the meaning given in regulation 8(1) of the 2012 Regulations.\n(6) This regulation does not apply to a small manufacturer or supplier.",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "F",
      "label": "F1",
      "text": "Reg. 3(1) substituted (1.1.2025) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2024 (S.I. 2024/1277), regs. 1(1), 4(2)"
    },
    {
      "type": "F",
      "label": "F2",
      "text": "Words in reg. 3(1) substituted (1.7.2025) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2025 (S.I. 2025/667), regs. 1(1), 3(2)(a)"
    },
    {
      "type": "F",
      "label": "F3",
      "text": "Reg. 3(1) Table substituted (1.7.2026) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2026 (S.I. 2026/614), regs. 1(1), 2(2)"
    },
    {
      "type": "F",
      "label": "F4",
      "text": "Reg. 3(1A) inserted (1.1.2019) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2018 (S.I. 2018/1255), regs. 1, 2(3)(c)"
    },
    {
      "type": "F",
      "label": "F5",
      "text": "Reg. 3(1AA) inserted (1.1.2025) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2024 (S.I. 2024/1277), regs. 1(1), 4(3)"
    },
    {
      "type": "F",
      "label": "F6",
      "text": "Reg. 3(1AB)(1AC) inserted (1.7.2025) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2025 (S.I. 2025/667), regs. 1(1), 3(3)"
    },
    {
      "type": "F",
      "label": "F7",
      "text": "Words in reg. 3(1AB) substituted (1.7.2026) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2026 (S.I. 2026/614), regs. 1(1), 2(3)(a)"
    },
    {
      "type": "F",
      "label": "F8",
      "text": "Words in reg. 3(1AB) substituted (1.7.2026) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2026 (S.I. 2026/614), regs. 1(1), 2(3)(b)"
    },
    {
      "type": "F",
      "label": "F9",
      "text": "Words in reg. 3(1AC) substituted (1.7.2026) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2026 (S.I. 2026/614), regs. 1(1), 2(4)(a)"
    },
    {
      "type": "F",
      "label": "F10",
      "text": "Words in reg. 3(1AC)(a) substituted (1.7.2026) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2026 (S.I. 2026/614), regs. 1(1), 2(4)(b)"
    },
    {
      "type": "F",
      "label": "F11",
      "text": "Word in reg. 3(1AC)(b) substituted (1.7.2026) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2026 (S.I. 2026/614), regs. 1(1), 2(4)(c)"
    },
    {
      "type": "F",
      "label": "F12",
      "text": "Reg. 3(1B) omitted (1.1.2024) by virtue of The Branded Health Service Medicines (Costs) (Amendment) (No. 2) Regulations 2023 (S.I. 2023/1307), regs. 1(1), 2(2)(b)"
    },
    {
      "type": "F",
      "label": "F13",
      "text": "Reg. 3(1C) omitted (1.1.2024) by virtue of The Branded Health Service Medicines (Costs) (Amendment) (No. 2) Regulations 2023 (S.I. 2023/1307), regs. 1(1), 2(2)(b)"
    },
    {
      "type": "F",
      "label": "F14",
      "text": "Words in reg. 3(4) substituted (1.1.2025) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2024 (S.I. 2024/1277), regs. 1(1), 4(4)"
    },
    {
      "type": "F",
      "label": "F15",
      "text": "Word in reg. 3(4)(d) substituted (1.1.2024) by The Branded Health Service Medicines (Costs) (Amendment) (No. 2) Regulations 2023 (S.I. 2023/1307), regs. 1(1), 2(2)(c)"
    },
    {
      "type": "F",
      "label": "F16",
      "text": "Reg. 3(4)(e)-(h) inserted (1.1.2024) by The Branded Health Service Medicines (Costs) (Amendment) (No. 2) Regulations 2023 (S.I. 2023/1307), regs. 1(1), 2(2)(c)"
    },
    {
      "type": "F",
      "label": "F17",
      "text": "Reg. 3(4A) inserted (1.1.2025) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2024 (S.I. 2024/1277), regs. 1(1), 4(5)"
    },
    {
      "type": "F",
      "label": "F18",
      "text": "Reg. 3(5A)-(5C) inserted (1.1.2019) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2018 (S.I. 2018/1255), regs. 1, 2(3)(d)"
    },
    {
      "type": "F",
      "label": "F19",
      "text": "Reg. 3(5D)-(5H) inserted (1.1.2024) by The Branded Health Service Medicines (Costs) (Amendment) (No. 2) Regulations 2023 (S.I. 2023/1307), regs. 1(1), 2(2)(d)"
    },
    {
      "type": "F",
      "label": "F20",
      "text": "Words in reg. 3(5H) inserted (1.1.2025) by The Branded Health Service Medicines (Costs) (Amendment) Regulations 2024 (S.I. 2024/1277), regs. 1(1), 4(6)"
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2018/345/regulation/3",
    "retrieved_at": "2026-10-28T23:00:23.214167+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}